Lyell Immunopharma (NASDAQ:LYEL) Rating Reiterated by HC Wainwright

Lyell Immunopharma (NASDAQ:LYEL)‘s stock had its “neutral” rating restated by research analysts at HC Wainwright in a research report issued on Monday, Benzinga reports. They presently have a $1.00 price objective on the stock. HC Wainwright’s target price points to a potential downside of 31.03% from the company’s previous close.

Separately, Bank of America decreased their price target on Lyell Immunopharma from $9.00 to $6.00 and set a “buy” rating on the stock in a research note on Thursday, June 27th.

Lyell Immunopharma Stock Down 0.7 %

Shares of Lyell Immunopharma stock opened at $1.45 on Monday. Lyell Immunopharma has a 52 week low of $1.18 and a 52 week high of $3.26. The business’s fifty day simple moving average is $1.66 and its 200-day simple moving average is $2.11. The firm has a market cap of $369.66 million, a PE ratio of -1.61 and a beta of -0.52.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.02. Lyell Immunopharma had a negative return on equity of 33.92% and a negative net margin of 335,794.09%. The business had revenue of $0.01 million for the quarter. As a group, equities analysts expect that Lyell Immunopharma will post -0.85 earnings per share for the current year.

Institutional Investors Weigh In On Lyell Immunopharma

Several institutional investors and hedge funds have recently modified their holdings of LYEL. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Lyell Immunopharma by 1,052.7% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 225,506 shares of the company’s stock valued at $437,000 after buying an additional 205,942 shares during the period. Simplicity Solutions LLC purchased a new stake in shares of Lyell Immunopharma in the 4th quarter valued at $93,000. WuXi AppTec Co. Ltd. purchased a new stake in Lyell Immunopharma during the 4th quarter worth about $15,871,000. Vanguard Personalized Indexing Management LLC purchased a new stake in Lyell Immunopharma during the 4th quarter worth about $31,000. Finally, RPO LLC purchased a new stake in Lyell Immunopharma during the 4th quarter worth about $38,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.